Search
元素搜索
结构搜索
Thermo Scientific Chemicals
Bortezomib, 98%
Bortezomib (CAS # 179324-69-7) is an inhibitor of protein degradation pathways. | CAS: 179324-69-7 | C19H25BN4O4 | 384.243 g/mol
| 货号 | 数量 |
|---|---|
| J60378.MA 又称 J60378-MA | 10 mg |
化学标识符
CAS179324-69-7
IUPAC Name[(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]butyl]boronic acid
Molecular FormulaC19H25BN4O4
InChI KeyGXJABQQUPOEUTA-RDJZCZTQSA-N
SMILESCC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
查看更多内容
规格
规格表
规格表Appearance (Color)White to off-white
Proton NMRConforms
FormPowder or crystals or crystalline powder
Assay from Suppliers CofA≥97.5%
A potent, highly selective and reversible inhibitor of the 20S proteasome, Bortezomib is used as an antineoplastic agent, which controls the growth of cancer cells. It is also useful in the treatment of multiple myeloma.
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
• Bortezomib is an antineoplastic compound derived from boronic acid
• Bortezomib reversibly inhibits the 26S proteostome that maintains cell cycle pathways related to growth and division
• Bortezomib is an inhibitor of NF-κB, a factor that is constituitively active in some cancers
Application
• Bortezomib is suitable for use in the research of multiple myeloma and lymphomas, and for use in the research of protein degradation pathways
• Bortezomib is intended for in vitro and biochemical applications
RUO – Research Use Only
General References:
- Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. PMID: 27557302.
- Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. PMID: 26671818.